Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has provided an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. successfully held its 2024 Annual General Meeting on May 22, 2025, where all proposed resolutions were passed by poll. The resolutions included the approval of various reports, profit distribution proposals, and amendments to share incentive schemes. The meeting was attended by a significant portion of shareholders, representing approximately 60.20% of the total shares with voting rights. The approval of these resolutions is expected to positively impact the company’s governance and operational strategies.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$3.88 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of heparin products and other pharmaceutical services. The company is based in China and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 2,506,922
Technical Sentiment Signal: Buy
Current Market Cap: HK$16.59B
Find detailed analytics on 9989 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue